Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis

References

• Döhner H, Weisdorf DJ, Bloomfield C. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Henderson E. Treatment of acute leukemia. in Seminars Hematol, 6: 271–319 (July 1969). 1969. National Cancer Inst., Bethesda, Md.
   Google Scholar
• Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051–1062.
   PubMed Web of Science ®Google Scholar
• Aldoss I. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018;103(9):e404.
   PubMed Web of Science ®Google Scholar
• Flotho C. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;23(6):1019–1028.
   PubMed Web of Science ®Google Scholar
• Hollenbach PW. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One. 2010;5:2.
   Web of Science ®Google Scholar
• Bohl SR, Bullinger L, Rücker F. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia. Expert Rev Hematol. 2018;11(5):361–371.
   PubMed Web of Science ®Google Scholar
• Issa J-PJ. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103(5):1635–1640.
   PubMed Web of Science ®Google Scholar
• Silverman LR. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. J Clin Oncol. 2006;24(24):3895–3903.
   PubMed Web of Science ®Google Scholar
• Gardin C, Dombret H. Hypomethylating agents as a therapy for AML. Curr Hematol Malig Rep. 2017;12(1):1–10.
   PubMed Web of Science ®Google Scholar
• Montalban-Bravo G, Garcia-Manero G. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93(1):129–147.
   PubMed Web of Science ®Google Scholar
• Balaian L, Ball EJL. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia. 2006;20(12):2093–2101.
   PubMed Web of Science ®Google Scholar
• Nand S. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma. 2008;49(11):2141–2147.
   PubMed Web of Science ®Google Scholar
• Sievers E. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate: presented in part at the 1997 Annual Meeting of the American Society of Clinical Oncology, Denver, CO; the 1997 European Cancer Conference, Hamburg, Germany; and the 1997 Annual Meeting of the American Society of Hematology, San Diego, CA. Blood, The Journal of the American Society of Hematology. 1999;93(11):3678–3684.
   Google Scholar
• Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–3254.
   PubMed Web of Science ®Google Scholar
• Jedema I. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia. 2004;18(2):316–325.
   PubMed Web of Science ®Google Scholar
• McGavin JK, Spencer CM. Gemtuzumab ozogamicin. Drugs. 2001;61(9):1317–1322.
   PubMed Web of Science ®Google Scholar
• van der Velden VH. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood J Am Soc Hematol. 2001;97(10):3197–3204.
   Google Scholar
• Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol. 2003;3(4):386–390.
   PubMed Web of Science ®Google Scholar
• Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011;17(20):6417–6427.
   PubMed Web of Science ®Google Scholar
• Food I. Drug administration %J safety concerns associated with Aranesp Amgen, and L. Procrit Ortho Biotech, for the treatment of anemia associated with cancer chemotherapy, Oncologic drugs advisory committee briefing document. 2004.
   Google Scholar
• Ishikawa T. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome. Int J Clin Oncol. 2014;19(1):10–15.
   PubMed Web of Science ®Google Scholar
• Michaelis LC. Azacitadine and low-dose gemtuzumab ozogamicin for the treatment of poor-risk acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), including relapsed, refractory disease. Blood. 2009;114(22):1034.
   Web of Science ®Google Scholar
• Borthakur G. Decitabine and gemtuzumab ozogamicin in acute myelogenous leukemia and high-risk myelodysplastic syndrome. Blood. 2008;112(11):2985–2985.
   Web of Science ®Google Scholar
• Chen Y. Phase II study of decitabine and gemtuzumab ozogamicin (GO) in acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). J Clin Oncol. 2010;28(Suppl. 15):6566–6566.
   Web of Science ®Google Scholar
• Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2009;84(9):599–600.
   PubMed Web of Science ®Google Scholar
• Nand S. A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood. 2013;122(20):3432–3439.
   PubMed Web of Science ®Google Scholar
• Fathi AT. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood. 2018;132(11):1125–1133.
   PubMed Web of Science ®Google Scholar
• Roland BW. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. Haematologica. 2014;99(1):54–59.
   PubMed Web of Science ®Google Scholar
• Medeiros BC. A phase I/II trial of the combination of azacitidine and gemtuzumab ozogamicin for treatment of relapsed acute myeloid leukemia. Clin Lymph Myeloma Leuk. 2018;18(5):346–352.
   PubMed Web of Science ®Google Scholar
• Amadori S. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34(9):972–979.
   PubMed Web of Science ®Google Scholar
• Larson RA. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442–1452.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP. Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk Lymph. 2004;45(9):1791–1795.
   PubMed Web of Science ®Google Scholar
• Taksin AL. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21(1):66–71.
   PubMed Web of Science ®Google Scholar
• Walter RB. Gemtuzumab ozogamicin in combination with Vorinostat and Azacitidine in older patients with relapsed or refractory Acute Myeloid Leukemia (AML): final results from a phase 1/2 study. Blood. 2013;122(21):3936.
   Google Scholar
• Cohen A. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant. 2002;30(1):23–28.
   PubMed Web of Science ®Google Scholar
• Nabhan C. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leuk Res. 2005;29(1):53–57.
   PubMed Web of Science ®Google Scholar
• Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–3254.
   PubMed Web of Science ®Google Scholar
• Amadori S. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). Br J Haematol. 2010;149(3):376–382.
   PubMed Web of Science ®Google Scholar
• Stone RM. The difficult problem of acute myeloid leukemia in the older adult. Cancer J Clin. 2002;52(6):363–371.
   PubMed Web of Science ®Google Scholar
• Hiddemann W. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17(11):3569–3576.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Stone R. Older adults with acute myeloid leukemia. Curr Oncol Rep. 2002;4(5):403–409.
   PubMedGoogle Scholar
• DiNardo CD. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Stein EM. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood J Am Soc Hematol. 2018;131(4):387–396.
   Google Scholar
• Fathi AT. Vadastuximab talirine plus hypomethylating agents: a well-tolerated regimen with high remission rate in frontline older patients with acute myeloid leukemia (AML). Washington (DC): American Society of Hematology. 2016.
   Google Scholar
• Bixby DL. Vadastuximab talirine monotherapy in older patients with treatment naive CD33-positive acute myeloid leukemia (AML)Washington (DC): American Society of Hematology. 2016.
   Google Scholar
• Feldman EJ. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23(18):4110–4116.
   PubMed Web of Science ®Google Scholar
• Raza A. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymph. 2009;50(8):1336–1344.
   PubMed Web of Science ®Google Scholar
• Whiteman KR. The antibody-drug conjugate (ADC) IMGN779 is highly active in vitro and in vivo against acute myeloid leukemia (AML) with FLT3-ITD mutationsWashington (DC): American Society of Hematology. 2014.
   Google Scholar
• Kovtun Y. IMGN779, a novel CD33-targeting antibody–drug conjugate with DNA-alkylating activity, exhibits potent antitumor activity in models of AML. Mol Cancer Ther. 2018;17(6):1271–1279.
   PubMed Web of Science ®Google Scholar